Skip to content
HowShorted

BIOCRYST PHARMACEUTICALS INC short interest in 2018

In 2018, BIOCRYST PHARMACEUTICALS INC's disclosed short interest ran from 12.21% of shares outstanding on 12 Jan 2018 to 8.87% on 31 Dec 2018, a change of -3.34 percentage points. The year's high was 12.21% on 12 Jan 2018 and its low 8.45% on 14 Dec 2018, averaging 10.14% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 24.73 days on 30 Apr 2018. Full history: BIOCRYST PHARMACEUTICALS INC.

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for BIOCRYST PHARMACEUTICALS INC in 2018

2018 in figures

Start of year
12.21% (12 Jan 2018)
End of year
8.87% (31 Dec 2018)
Change
-3.34 pp
High
12.21% (12 Jan 2018)
Low
8.45% (14 Dec 2018)
Average
10.14%
Highest days to cover
24.73 (30 Apr 2018)
SEC filings marked
8

Every report in 2018

BIOCRYST PHARMACEUTICALS INC short interest in 2018
SettlementShort interestDays to coverFilings since previous
12 Jan 201812.21%9.57
31 Jan 201810.91%6.44
15 Feb 201811.86%7.86
28 Feb 201812.21%11.49results (8-K)
15 Mar 201811.22%11.4410-K filed
29 Mar 201810.95%12.99
13 Apr 201810.84%12.60
30 Apr 201811.04%24.73
15 May 201810.69%12.19results (8-K), 10-Q filed
31 May 201810.36%11.91
15 Jun 201810.44%11.84
29 Jun 201810.03%11.13
13 Jul 20189.73%14.60
31 Jul 20189.34%20.26
15 Aug 20189.67%7.05results (8-K), 10-Q filed
31 Aug 20189.63%18.24
14 Sep 20189.35%13.21
28 Sep 20189.73%18.53
15 Oct 20189.71%22.77
31 Oct 20188.77%22.26
15 Nov 20188.55%17.47results (8-K), 10-Q filed
30 Nov 20188.77%9.89
14 Dec 20188.45%15.47
31 Dec 20188.87%10.90

See also: BIOCRYST PHARMACEUTICALS INC's full history · most shorted US stocks of 2018 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.